
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis</strong></summary>
            <div>
                <ul><li>- European Association for the Study of the Liver</li><li>- Journal of Hepatology 2017 vol. 67 j 145–172</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended daily dose of <b>Ursodeoxycholic acid</b> (UDCA) for PBC?</li><li>- What is the 5-year patient survival rate after liver transplantation for PBC?</li><li>- What percentage of PBC patients experience severe, debilitating fatigue?</li><li>- According to the POISE trial, what percentage of patients on the <b>Obeticholic acid</b> (OCA) 10mg arm met the primary endpoint, compared to placebo?</li><li>- What is the estimated incidence of Hepatocellular Carcinoma (HCC) in PBC patients, in cases per 1,000 patient-years?</li><li>- What is the 4-year probability of developing oesophageal varices in UDCA-treated patients versus untreated patients?</li><li>- What is the threshold for Liver Stiffness Measurement (LSM) that is associated with a 5-fold increased risk of liver decompensation?</li><li>- What percentage of patients with PBC also have features of Autoimmune Hepatitis (AIH)?</li><li>- What is the approximate rate of PBC recurrence in patients after liver transplantation?</li><li>- What is the recommended starting dose for <b>Obeticholic acid</b> (OCA) and how is it titrated?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction to Primary Biliary Cholangitis (PBC)</strong></summary>
            <div>
                <ul><li>- A chronic, progressive, autoimmune cholestatic liver disease.</li><li>- Predominantly affects women, with an estimated global prevalence of <q><u>1 in 1,000 women over 40</u></q>.</li><li>- Untreated, it can culminate in end-stage biliary cirrhosis.</li></ul>
                
        <details>
            <summary><strong>Key Characteristics</strong></summary>
            <div>
                <ul><li>- <b>Cholestasis</b>: Impaired bile formation and/or flow.</li><li>- <b>Serologic Reactivity</b>: Presence of antimitochondrial antibodies (AMA) or specific antinuclear antibodies (ANA).</li><li>- <b>Histology</b>: Chronic, non-suppurative, granulomatous, lymphocytic inflammation of small bile ducts.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Epidemiology</strong></summary>
            <div>
                <ul><li>- European incidence: <q><b>1–2 per 100,000</b></q> population per year.</li><li>- Prevalence: <q><b>1.9–40.2 per 100,000</b></q>.</li><li>- Female predominance, though male prevalence may be increasing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Pathogenesis</strong></summary>
            <div>
                <ul><li>- A cycle of immune-mediated biliary injury, cholestasis, and fibrosis.</li><li>- Involves interaction of immune (T-cells, B-cells, AMA production) and biliary pathways (impaired bicarbonate umbrella, AE2 downregulation).</li><li>- Gut-liver axis involvement via the <b>FXR/FGF-19</b> signalling pathway.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Impact & Prognosis</strong></summary>
            <div>
                <ul><li>- <b>Disease Progression</b>: Leads to cirrhosis and need for liver transplantation.</li><li>- <b>Symptoms</b>: Significant impact on Quality of Life (QoL), including pruritus, sicca complex, and fatigue.</li></ul>
                
        <details>
            <summary><strong>Prognosis without Treatment</strong></summary>
            <div>
                <ul><li>- Historic cohorts showed average survival of <q><b>9–10 years</b></q> from presentation.</li><li>- <q><u>25% developed liver failure</u></q> during this time.</li><li>- Median time to develop extensive fibrosis is <q><b>2 years</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prognosis with UDCA Treatment</strong></summary>
            <div>
                <ul><li>- 10-year survival approaches <q><b>80%</b></q>.</li><li>- Progression to cirrhosis after 6 years is significantly lower (<q><u>1 in 10 on UDCA</u></q> vs. 1 in 2 on placebo).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnostic Approach to Cholestasis</strong></summary>
            <div>
                <ul><li>- A structured, systematic approach is recommended for any patient with chronic cholestasis (lasting <q><u>>6 months</u></q>).</li></ul>
                
        <details>
            <summary><strong>Initial Evaluation</strong></summary>
            <div>
                <ul><li>- <b>History & Physical Exam</b>: Look for clues of associated diseases (e.g., Sjögren's with PBC, IBD with PSC), drug history (DILI), and signs of advanced liver disease (icterus, xanthelasma).</li><li>- <b>Biochemical Markers</b>: Initial signs are elevated serum <u>ALP</u> and <u>GGT</u>. Conjugated hyperbilirubinemia occurs at more advanced stages.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Imaging</strong></summary>
            <div>
                <ul><li>- <b>Abdominal Ultrasound</b>: <u>First-line</u> imaging to exclude mechanical bile duct obstruction. A normal ultrasound suggests intrahepatic cholestasis.</li><li>- <b>Magnetic Resonance Cholangiopancreatography (MRCP)</b>: Recommended for detailed imaging of the biliary tree if cholestasis is unexplained. Essential for diagnosing sclerosing cholangitis.</li><li>- <b>Endoscopic Ultrasound (EUS)</b>: An alternative to MRCP, particularly for evaluating the distal bile duct.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Serological & Further Testing</strong></summary>
            <div>
                <ul><li>- <b>Serology</b>: Screen for <b>AMA</b> and PBC-specific <b>ANA</b> in all patients with unexplained cholestasis.</li><li>- <b>Liver Biopsy</b>: Consider if serology and imaging do not yield a diagnosis. An adequate sample should contain <q><u>at least 11 portal fields</u></q>.</li><li>- <b>Genetic Testing</b>: Reserved for specialist centers when inherited syndromes (e.g., PFIC, BRIC) are suspected.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Specific Diagnosis of PBC</strong></summary>
            <div>
                <ul><li>- Diagnosis is based on a combination of cholestatic liver tests and specific immunological markers.</li></ul>
                
        <details>
            <summary><strong>Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- A diagnosis of PBC can be made in an adult with elevated <b>ALP</b> and the presence of <b>AMA</b> at a titre of <q><u>≥1:40</u></q>.</li><li>- Liver biopsy is <u>not necessary</u> for diagnosis in this context.</li></ul>
                
        <details>
            <summary><strong>AMA-Negative PBC</strong></summary>
            <div>
                <ul><li>- Accounts for <q><b>5-10%</b></q> of cases.</li><li>- Diagnosis can be made in patients with cholestasis and specific <b>ANA</b> patterns (<u>nuclear dots</u> or <u>perinuclear rims</u>) or positive ELISA for <u>sp100</u> or <u>gp210</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of Liver Biopsy</strong></summary>
            <div>
                <ul><li>- Biopsy is recommended when:</li><li>- PBC-specific antibodies are absent.</li><li>- Co-existent <b>AIH</b> or <b>NASH</b> is suspected.</li><li>- Other systemic co-morbidities are present.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Investigations (Table 4)</strong></summary>
            <div>
                <ul><li>- <b>Biochemistry</b>: Elevated <u>ALP</u> is typical. AST/ALT may be elevated (AST/ALT ratio <q><u>>1</u></q> may suggest fibrosis). Elevated <u>IgM</u> is common. <u>Bilirubin</u> rises in late-stage disease.</li><li>- <b>Immunology</b>: <b>AMA</b> is the diagnostic hallmark, positive in <q><u>>90%</u></q> of patients. Specific <b>ANA</b> (anti-gp210, anti-sp100) are highly specific.</li><li>- <b>Histology</b>: The characteristic feature is the '<u>florid duct lesion</u>' (non-suppurative destructive cholangitis). Staging systems (Ludwig, Scheuer, Nakanuma) assess fibrosis and bile duct loss.</li></ul>
                
        <details>
            <summary><strong>Isolated AMA Positivity</strong></summary>
            <div>
                <ul><li>- AMA reactivity alone with normal liver tests is <u>not sufficient</u> to diagnose PBC.</li><li>- These individuals should be followed up with <q><u>annual biochemical reassessment</u></q>.</li><li>- Only <q><u>one in six</u></q> such patients develops PBC within 5 years.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk Stratification</strong></summary>
            <div>
                <ul><li>- All patients should be evaluated for their risk of disease progression to guide management and need for second-line therapies.</li></ul>
                
        <details>
            <summary><strong>High-Risk Patient Profile</strong></summary>
            <div>
                <ul><li>- <b>Demographics</b>: Younger age at diagnosis (<q><u><45 years</u></q>) and <u>male sex</u> are associated with poorer response and outcomes.</li><li>- <b>Disease Stage</b>: Advanced stage at presentation is a strong risk factor.</li><li>- <b>Biochemical Response</b>: Inadequate response to UDCA therapy is the most critical factor.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Prognostic Tools</strong></summary>
            <div>
                <ul><li>- A combination of non-invasive tests should be used at baseline and during follow-up.</li></ul>
                
        <details>
            <summary><strong>Biochemical Markers</strong></summary>
            <div>
                <ul><li>- <b>ALP and Bilirubin</b> are the strongest surrogate markers for outcome.</li><li>- <b>Albumin</b> and <b>platelet count</b> are also key indicators of disease stage.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Stiffness Measurement (LSM)</strong></summary>
            <div>
                <ul><li>- Measured by Vibration-Controlled Transient Elastography (VCTE).</li><li>- An excellent surrogate marker for fibrosis and cirrhosis.</li><li>- LSM <q><u>>9.6 kPa</u></q> is associated with a <q><b>5-fold increased risk</b></q> of liver decompensation, transplant, or death.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Assessing Response to UDCA</strong></summary>
            <div>
                <ul><li>- Response is typically assessed after <q><b>1 year</b></q> of therapy (though 6 months may be equivalent).</li><li>- Inadequate response is seen in <q><b>25% to 50%</b></q> of patients.</li></ul>
                
        <details>
            <summary><strong>Qualitative Criteria (Table 5)</strong></summary>
            <div>
                <ul><li>- <b>Paris-I</b>: Widely validated. Failure is defined as ALP <q><u>≥3x ULN</u></q> OR AST <q><u>≥2x ULN</u></q> OR Bilirubin <q><u>>1 mg/dl</u></q>.</li><li>- <b>Paris-II</b>: Designed for early-stage disease. Failure is defined as ALP <q><u>≥1.5x ULN</u></q> OR AST <q><u>≥1.5x ULN</u></q> OR Bilirubin <q><u>>1 mg/dl</u></q>.</li><li>- Patients with ALP <1.5x ULN and normal bilirubin after 1 year of UDCA have a survival rate similar to the general population.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Continuous Risk Scores (Table 5)</strong></summary>
            <div>
                <ul><li>- <b>GLOBE Score</b> and <b>UK-PBC Score</b> incorporate on-treatment biochemistry and baseline severity markers.</li><li>- They offer better performance than binary criteria for predicting death or transplant.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment to Slow Disease Progression</strong></summary>
            <div>
                <ul><li>- The goal of therapy is to prevent end-stage liver disease complications.</li></ul>
                
        <details>
            <summary><strong>First-Line Therapy: Licensed</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Ursodeoxycholic Acid (UDCA)</strong></summary>
            <div>
                <ul><li>- Recommended as <u>first-line pharmacotherapy</u> for <b>ALL</b> patients with PBC, usually for life.</li></ul>
                
        <details>
            <summary><strong>Dose & Safety</strong></summary>
            <div>
                <ul><li>- Dose: <q><b>13–15 mg/kg/day</b></q>, can be given as a single daily dose.</li><li>- Safety: Very safe, minimal side effects. Considered safe in pregnancy and breastfeeding.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy</strong></summary>
            <div>
                <ul><li>- Reduces risk of death or transplant by <q><u>one-third</u></q> in moderate-to-severe disease.</li><li>- Slows histological progression: 4-year probability of remaining in early-stage disease is <q><b>76%</b></q> (vs. 29% on placebo).</li><li>- Reduces risk of oesophageal varices: 4-year probability is <q><b>16%</b></q> (vs. 58% in untreated).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Second-Line Therapy: Licensed</strong></summary>
            <div>
                <ul><li>- For patients with an inadequate response to UDCA or who are intolerant.</li></ul>
                
        <details>
            <summary><strong>Obeticholic Acid (OCA)</strong></summary>
            <div>
                <ul><li>- A semi-synthetic bile acid analogue that is a potent and selective <b>FXR agonist</b>.</li></ul>
                
        <details>
            <summary><strong>Indication & Dose</strong></summary>
            <div>
                <ul><li>- Approved for use in combination with UDCA or as monotherapy.</li><li>- Starting dose: <q><b>5 mg daily</b></q>.</li><li>- Titration: Increase to <q><b>10 mg daily</b></q> after 6 months, according to tolerability.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Efficacy (POISE Trial)</strong></summary>
            <div>
                <ul><li>- For patients with ALP <q><u>≥1.67x ULN</u></q> and/or elevated bilirubin <q><u><2x ULN</u></q>.</li><li>- Primary endpoint met in <q><b>47%</b></q> (10mg group) and <q><b>46%</b></q> (5-10mg group) vs. <q><b>10%</b></q> in placebo group.</li><li>- Mean decrease in ALP was <q><b>39%</b></q> in the 10mg group vs. 5% for placebo.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Side Effects</strong></summary>
            <div>
                <ul><li>- <b>Pruritus</b>: Dose-dependent, leading to discontinuation in <q><b>1-10%</b></q> of patients.</li><li>- <b>Lipid Changes</b>: Reversible decrease in HDL cholesterol.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Off-Label / Unlicensed Therapies</strong></summary>
            <div>
                <ul><li>- Data are not yet sufficient for a formal recommendation.</li></ul>
                
        <details>
            <summary><strong>Budesonide</strong></summary>
            <div>
                <ul><li>- A corticosteroid with high first-pass metabolism.</li><li>- Considered for non-cirrhotic patients with features of AIH (interface hepatitis).</li><li>- Efficacy data is mixed; can improve histology but may worsen bone density. <u>Avoid in patients with cirrhosis</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fibric Acid Derivatives (Fibrates)</strong></summary>
            <div>
                <ul><li>- e.g., Bezafibrate, Fenofibrate. Act as <b>PPAR activators</b>.</li><li>- Can significantly improve biochemistry (e.g., normalize ALP) in UDCA non-responders.</li><li>- Long-term benefit on clinical outcomes is not yet proven; concerns exist regarding potential renal and liver toxicity.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management in Special Settings</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Pregnancy</strong></summary>
            <div>
                <ul><li>- Typically well-tolerated in <u>non-cirrhotic</u> patients.</li><li>- <b>UDCA</b> should be continued as it is considered safe.</li><li>- Pruritus can worsen; <b>cholestyramine</b> is safe, and <b>rifampicin</b> can be used in the <q><u>third trimester</u></q>.</li><li>- Patients with <b>cirrhosis</b> have higher risks and require pre-conception counselling and specialist monitoring, including variceal screening in the second trimester.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>PBC with Features of Autoimmune Hepatitis (AIH)</strong></summary>
            <div>
                <ul><li>- Occurs in <q><b>~8-10%</b></q> of patients with PBC.</li><li>- A <u>liver biopsy is mandatory</u> for diagnosis.</li></ul>
                
        <details>
            <summary><strong>Diagnosis (Paris Criteria)</strong></summary>
            <div>
                <ul><li>- Requires meeting criteria for both diseases.</li><li>- <b>PBC features (≥2 of 3)</b>: ALP ≥2x ULN or GGT ≥5x ULN; AMA ≥1:40; Florid duct lesion.</li><li>- <b>AIH features (≥2 of 3)</b>: ALT ≥5x ULN; IgG ≥2x ULN or positive SMA; Moderate/severe interface hepatitis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment</strong></summary>
            <div>
                <ul><li>- Patients may benefit from <b>immunosuppressive treatment</b> in addition to UDCA.</li><li>- Immunosuppression is suggested for <u>severe interface hepatitis</u> and should be considered for <u>moderate interface hepatitis</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Symptoms & Extrahepatic Manifestations</strong></summary>
            <div>
                <ul><li>- Symptoms often do <u>not correlate</u> with disease severity and do <u>not improve</u> with UDCA or OCA.</li><li>- A structured approach to symptom evaluation and management is essential.</li></ul>
                
        <details>
            <summary><strong>Pruritus (Itch)</strong></summary>
            <div>
                <ul><li>- A characteristic cholestatic symptom. Severe pruritus may indicate an aggressive ductopenic variant with a poor prognosis.</li></ul>
                
        <details>
            <summary><strong>Stepwise Treatment Approach</strong></summary>
            <div>
                <ul><li>- <b>1st Line</b>: <u>Cholestyramine</u> (bile acid sequestrant). Must be taken <q><b>2-4 hours</b></q> apart from other medications.</li><li>- <b>2nd Line</b>: <u>Rifampicin</u> (<q><b>150-300 mg daily</b></q>). Requires monitoring of liver tests due to potential hepatotoxicity.</li><li>- <b>3rd Line</b>: <u>Naltrexone</u> (oral opiate antagonist). Start at a low dose.</li><li>- <b>Other</b>: Sertraline (SSRI) used empirically.</li><li>- <b>Refractory Cases</b>: May require referral for experimental therapies or consideration for liver transplantation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fatigue</strong></summary>
            <div>
                <ul><li>- Frequently reported (<q><u>>50%</u></q> of patients) and can be debilitatingly severe in <q><b>20%</b></q>.</li><li>- Not related to liver disease severity (except in end-stage disease) and persists post-transplant.</li><li>- Management focuses on treating associated causes (anaemia, hypothyroidism, sleep disturbance) and developing coping strategies.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sicca Complex (Dryness)</strong></summary>
            <div>
                <ul><li>- Dry eyes and/or dry mouth are common.</li><li>- Management includes artificial tears/saliva. Refractory cases may use <b>pilocarpine</b> or <b>cevimeline</b>.</li><li>- Good oral hygiene is important to prevent dental caries.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Liver Disease Complications</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Osteoporosis</strong></summary>
            <div>
                <ul><li>- A common complication. All patients should have arisk assessment for osteoporosis.</li><li>- <b>DEXA scan</b> is recommended at presentation to assess bone mineral density, with follow-up intervals of <q><b>1 to 5 years</b></q> depending on risk.</li><li>- Treatment with <b>bisphosphonates</b> is effective but should be used with caution in patients with oesophageal varices.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fat-Soluble Vitamin Deficiency</strong></summary>
            <div>
                <ul><li>- Deficiencies in vitamins A, D, E, and K are <u>uncommon</u> in PBC.</li><li>- Risk is higher in patients with prolonged jaundice.</li><li>- Supplementation should be considered on an individual basis, with a lower threshold for icteric patients.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hyperlipidaemia</strong></summary>
            <div>
                <ul><li>- Elevated serum lipids occur in up to <q><b>80%</b></q> of patients but is not associated with an increased cardiovascular risk.</li><li>- This is partly due to the presence of an anti-atherogenic particle, <u>lipoprotein X</u>.</li><li>- Treatment is generally not required unless the patient has concomitant classical cardiovascular risk factors.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Varices & Portal Hypertension</strong></summary>
            <div>
                <ul><li>- Portal hypertension can develop in pre-cirrhotic stages, though this is rare.</li><li>- The <b>Baveno-VI guidelines</b> for screening and management of varices apply to patients with PBC.</li><li>- Screening is indicated for patients with LSM <q><u>≥20 kPa</u></q> or a platelet count <q><u><150 x 10⁹ cells/L</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hepatocellular Carcinoma (HCC)</strong></summary>
            <div>
                <ul><li>- Patients with cirrhosis are at risk of developing HCC.</li><li>- Incidence is estimated at <q><b>3.4 cases per 1,000 patient-years</b></q>.</li><li>- Key risk factors are <u>male sex</u>, <u>inadequate response to UDCA</u>, and <u>cirrhosis</u>.</li><li>- Surveillance with ultrasound every <q><b>6 months</b></q> is recommended for patients with cirrhosis, per EASL guidelines.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Liver Transplantation</strong></summary>
            <div>
                <ul><li>- The need for transplantation in PBC has declined with effective medical therapy.</li></ul>
                
        <details>
            <summary><strong>Indications for Assessment</strong></summary>
            <div>
                <ul><li>- <b>Decompensated Cirrhosis</b>: Variceal bleed, ascites, encephalopathy.</li><li>- <b>Markers of Severity</b>: MELD score <q><u>≥15</u></q> or persistent bilirubin <q><u>>50 µmol/L (3 mg/dl)</u></q>.</li><li>- <b>Symptoms</b>: Severe, medically intractable pruritus.</li><li>- <u>Fatigue is NOT an indication</u> for transplantation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes & Post-Transplant Management</strong></summary>
            <div>
                <ul><li>- Outcomes are favorable, with 5-year patient survival rates of <q><b>80-85%</b></q>.</li><li>- <b>PBC Recurrence</b>: Occurs in <q><u>~20%</u></q> of patients but rarely leads to graft loss. UDCA may be used for recurrent PBC.</li><li>- <b>Symptoms</b>: Fatigue frequently persists after transplantation.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Organisation of Clinical Care</strong></summary>
            <div>
                <ul><li>- A structured, life-long, and individualized approach to care is essential.</li></ul>
                
        <details>
            <summary><strong>Care Pathways</strong></summary>
            <div>
                <ul><li>- All patients should have at least an <u>annual assessment</u> of their disease status, treatment needs, and symptoms.</li><li>- Care pathways should be developed to ensure equitable and effective care, ranging from primary care to tertiary centers based on patient risk.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Audit Standards</strong></summary>
            <div>
                <ul><li>- Proposed standards to improve quality of care:</li></ul>
                
        <details>
            <summary><strong>Diagnosis & Initial Management</strong></summary>
            <div>
                <ul><li>- <b>Ultrasound</b> at baseline: <q><u>Standard 90%</u></q>.</li><li>- <b>UDCA</b> at 13-15 mg/kg/day: <q><u>Standard 90%</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Risk & Symptom Assessment</strong></summary>
            <div>
                <ul><li>- <b>Risk stratification</b> after 1 year of UDCA: <q><u>Standard 80%</u></q>.</li><li>- <b>Symptom evaluation</b> (pruritus, sicca, fatigue) annually: <q><u>Standard 90%</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Advanced Disease Management</strong></summary>
            <div>
                <ul><li>- <b>Transplant discussion</b> for bilirubin >50 µmol/L or decompensation: <q><u>Standard 90%</u></q>.</li><li>- <b>Osteoporosis risk assessment</b> within last 5 years: <q><u>Standard 80%</u></q>.</li><li>- <b>Liver biopsy</b> for suspected AIH overlap: <q><u>Standard 90%</u></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Support</strong></summary>
            <div>
                <ul><li>- Patients should be informed about patient support groups and educational materials.</li><li>- Fatigue has the biggest impact on QoL; coping strategies and addressing social isolation are important.</li><li>- Patients with profound psychological distress should be referred to appropriate services.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>- PBC is a common cause of chronic cholestasis, primarily in women over 40.</li><li>- Diagnosis relies on biochemical and serologic findings, with UDCA as the cornerstone of therapy.</li><li>- Risk stratification is critical to identify patients needing second-line therapy (e.g., OCA).</li><li>- A holistic, life-long approach is needed, focusing on both slowing disease progression and managing debilitating symptoms.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
